Chemnitz

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis3 trials
• Coronary artery disease2 trials
• Stroke2 trials
• Diabetic eye disease1 trial
• Familial hypercholesterolaemia1 trial
• Heart failure1 trial
• Hidradenitis suppurativa1 trial
• Macular degeneration1 trial
• Melanoma1 trial
• Metastatic breast cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 33 trials

Status

• Completed6 trials
• Active, not recruiting4 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Novartis Pharmaceuticals12 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

  NCT06551519· Novartis Pharmaceuticals· Source

• Recruiting

  Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

  NCT06517719· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

  NCT05921994· Novartis Pharmaceuticals· Source

• Recruiting

  A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

  NCT05344469· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer1 recruiting

Closed trials

• Completed

  Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care

  NCT06004453· Novartis Pharmaceuticals· Source

• Completed

  Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies

  NCT05566756· Novartis Pharmaceuticals· Source

• Completed

  A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

  NCT05362903· Novartis Pharmaceuticals· Source

• Completed

  Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

  NCT04543331· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

  NCT06311383· Novartis Pharmaceuticals· Source

• Terminated

  A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

  NCT02967692· Phase 3· Novartis Pharmaceuticals· Source